© 2004 by Oxford University Press
© 2004 Oxford University Press
BRIEF COMMUNICATION |
Skin Cancers and Non-Hodgkin Lymphoma Among Users of Systemic Glucocorticoids: A Population-Based Cohort Study
Affiliations of authors: Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark (HTS, GLN); Institute of Cancer Epidemiology, The Danish Cancer Society, Copenhagen, Denmark (LM, JHO); Department of Medicine and Community and Family Medicine, and the Norris Cotton Cancer Center, Dartmouth Medical School, Hanover, NH (JAB, MRK).
Correspondence to: Henrik Toft Sørensen, MD, PhD, Department of Clinical Epidemiology, Aarhus University Hospital, Vennelyst Boulevard 6, Bldg. 260, DK-8000 Aarhus C, Denmark (e-mail: hts{at}soci.au.dk)
Patients treated with glucocorticoids may have an increased risk of skin cancer. Using data from the population-based North Jutland Prescription Database and the Danish Cancer Registry, we compared observed and expected numbers of cases of skin cancer and non-Hodgkin lymphoma among 59 043 individuals who received prescriptions for glucocorticoids, a common immunosuppressive therapy, during an 8-year period from January 1, 1989, through December 31, 1996. The overall risks for squamous cell carcinomas and basal cell carcinomas of the skin were increased, particularly among persons who had 15 or more prescriptions (standardized incidence ratio [SIR] for squamous cell carcinomas = 2.45, 95% confidence interval [CI] = 1.37 to 4.04; SIR for basal cell carcinomas = 1.52, 95% CI = 1.09 to 2.07). An elevated risk was also found for non-Hodgkin lymphoma among those with 10–14 prescriptions (SIR = 2.68, 95% CI = 1.16 to 5.29). Our data suggest that use of glucocorticoids may be a shared risk factor for certain skin cancers and lymphomas.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. E. Smedby, E. Baecklund, and J. Askling Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics. Cancer Epidemiol. Biomarkers Prev., November 1, 2006; 15(11): 2069 - 2077. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Paul, M. Cork, A. B. Rossi, K. A. Papp, N. Barbier, and Y. de Prost Safety and Tolerability of 1% Pimecrolimus Cream Among Infants: Experience With 1133 Patients Treated for Up to 2 Years Pediatrics, January 1, 2006; 117(1): e118 - e128. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. A. Engels, J. R. Cerhan, M. S. Linet, W. Cozen, J. S. Colt, S. Davis, G. Gridley, R. K. Severson, and P. Hartge Immune-Related Conditions and Immune-Modulating Medications as Risk Factors for Non-Hodgkin's Lymphoma: A Case-Control Study Am. J. Epidemiol., December 15, 2005; 162(12): 1153 - 1161. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J Askling, L Klareskog, H Hjalgrim, E Baecklund, M Bjorkholm, and A Ekbom Do steroids increase lymphoma risk? A case-control study of lymphoma risk in polymyalgia rheumatica/giant cell arteritis Ann Rheum Dis, December 1, 2005; 64(12): 1765 - 1768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Sorensen, L. Mellemkjaer, M. V. Skriver, T. L. Lash, J. H. Olsen, and J. A. Baron No Excess Risk of Breast Cancer among Female Users of Systemic Glucocorticoids Cancer Epidemiol. Biomarkers Prev., April 1, 2005; 14(4): 1022 - 1023. [Full Text] [PDF]
|
|
|
|
 |
|
 A. A. Fryer, H. M. Ramsay, T. J. Lovatt, P. W. Jones, C. M. Hawley, D. L. Nicol, R. C. Strange, and P. N. Harden Polymorphisms in glutathione S-transferases and non-melanoma skin cancer risk in Australian renal transplant recipients Carcinogenesis, January 1, 2005; 26(1): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kobayashi, K. Takahashi, N. Mizuno, H. Kutsuna, and M. Ishii An Alternative Approach to Atopic Dermatitis: Part II--Summary of Cases and Discussion Evid. Based Complement. Altern. Med., September 1, 2004; 1(2): 145 - 155. [Abstract] [Full Text] [PDF]
|
|